Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers

Takeuchi, Satoshi; Rohren, Eric M.; Abdel-Wahab, Reham; Xiao, Lianchun; Morris, Jeffrey S.; Macapinlac, Homer A.; Hassan, Manal M.; Kaseb, Ahmed O.

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers

Takeuchi, Satoshi; Rohren, Eric M.; Abdel-Wahab, Reham et al.

European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44(6), 969-978

Permalink : https://hdl.handle.net/2115/70645

このアイテムのアクセス数:641件（2026-08-15 09:34 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
EurJNuclMedMolImaging44_969	pdf	484 KB	519

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/70645
タイトル	Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers
著者	Takeuchi, Satoshi ; Rohren, Eric M. ; Abdel-Wahab, Reham ; Xiao, Lianchun ; Morris, Jeffrey S. ; Macapinlac, Homer A. ; Hassan, Manal M. ; Kaseb, Ahmed O.
著者名 Takeuchi, Satoshi
著者名 Rohren, Eric M.
著者名 Abdel-Wahab, Reham
著者名 Xiao, Lianchun
著者名 Morris, Jeffrey S.
著者名 Macapinlac, Homer A.
著者名 Hassan, Manal M.
著者名 Kaseb, Ahmed O.
言語	英語
キーワード	FDG PET/CT
	Hepatocellular carcinoma
	CLIP scoring system
	BCLC staging system
発行日	2017-06
出版者	Springer
収録物名	European Journal of Nuclear Medicine and Molecular Imaging
巻(号)	44(6)
ページ	969-978
抄録	Purpose: 18F-fluorodeoxyglucose positron emission tomopraphy/computed tomography (FDGPET/CT) has been proven to be useful for imaging many types of cancer; however, its role is not well defined in hepatocellular carcinoma (HCC). We assessed the prognostic value of metabolic imaging biomarkers as established by baseline pretreatment FDG PET/CT in patients with HCC. Methods: We retrospectively analyzed the records of patients with HCC who underwent FDG PET/CT before initial treatment from May 2013 through May 2014. Four PET/CT parameters were measured: maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), metabolic tumor volume (MTV), and tumor-to-normal-liver SUV ratio (TNR). Optimal cut-off values for the PET/CT parameters to stratify patients in terms of overall survival (OS) were determined. Multivariate analysis was performed to determine whether the PET/CT parameters could add to the prognostic value of the Cancer of the Liver Italian Program (CLIP) scoring system and the Barcelona-Clinic Liver Cancer (BCLC) staging system. Results: The analysis included 56 patients. Univariate analysis of the association between OS and continuous variables, including the PET/CT parameters SUVmax, TLG, tumor size, total bilirubin level, and alkaline phosphatase level were significant predictors of OS. SUVmax ≥ 11.7, TLG ≥ 1,341, MTV ≥ 230 mL, and TNR ≥ 4.8 were identified as cut-off values. Multivariate analysis revealed that SUVmax ≥ 11.7 and TNR ≥ 4.8 were independent factors predicting a poor prognosis in both the CLIP scoring system and the BCLC staging system, as was TLG in the BCLC staging system. Conclusion: Pretreatment FDG PET/CT in patients with HCC can add to the prognostic value of standard clinical measures. Incorporation of imaging biomarkers derived from FDG PET/CT into HCC staging systems should be considered.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	The final publication is available at link.springer.com
PISSN	1619-7070
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s00259-016-3583-2